Spero Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
SPRO$1.01-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Convertible Preferred Shares and Stockholders’ Equity
STOCKHOLDERS’ EQUITY
(In thousands, except unit and share amounts)
| Series A, B, C and D · Additional · Accumulated · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Convertible Preferred Stock · Common Stock · Paid-in · Accumulated · Other Comprehensive · Stockholders' | ||||||||
| Shares | Par Value | Shares | Par Value | Capital | Deficit | Income (Loss) | Equity | |
| Balances at December 31, 2021 | 3,218,152 | 3 | 32,393,738 | 32 | 455,719 | (367,463) | (2) | 88,289 |
| Issuance of common stock upon the exercise of stock options | — | — | 56,120 | — | 420 | — | — | 420 |
| Issuance of common stock upon the vesting of restricted stock units and performance stock units | — | — | 226,043 | — | — | — | — | — |
| Issuance of common stock, net of issuance costs | — | — | 5,963,294 | 7 | 14,227 | — | — | 14,234 |
| Issuance of common stock under GSK Share Purchase Agreement, net of discount of $1.3 million | — | — | 7,450,000 | 7 | 10,271 | — | — | 10,278 |
| Conversion of convertible preferred stock to common stock | (3,218,152) | (3) | 6,367,000 | 6 | — | — | — | 3 |
| Share-based compensation expense | — | — | — | — | 9,123 | — | — | 9,123 |
| Unrealized gain on available-for-sale securities | — | — | — | — | — | — | 2 | 2 |
| Net income (loss) | — | — | — | — | — | (46,415) | — | (46,415) |
| Balances at December 31, 2022 | — | — | 52,456,195 | 52 | 489,760 | (413,878) | — | 75,934 |
| Issuance of common stock upon the exercise of stock options | — | — | — | — | — | — | — | — |
| Issuance of common stock upon the vesting of restricted stock units and performance stock units | — | — | 399,009 | 1 | — | — | — | 1 |
| Issuance of common stock, net of issuance costs | — | — | 144,476 | — | 221 | — | — | 221 |
| Share-based compensation expense | — | — | — | — | 7,932 | — | — | 7,932 |
| Unrealized gain on available-for-sale securities | — | — | — | — | — | — | — | — |
| Net income (loss) | — | — | — | — | — | 22,806 | — | 22,806 |
| Balances at December 31, 2023 | — | — | 52,999,680 | 53 | 497,913 | (391,072) | — | 106,894 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.